Stay updated with breaking news from Genentech Lucentis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- The switch landscape represents an active segment of the market where brands have the opportunity to capture share. Spherix's RealWorld...
/PRNewswire/ -- Ophthalmologists saw the entry of the first biosimilars into the armamentarium in 2022 with the launch of Biogen and Samsung's Byooviz and...
/PRNewswire/ -- Ophthalmologists saw the entry of the first biosimilars into the armamentarium in 2022 with the launch of Biogen and Samsung's Byooviz and...
/PRNewswire/ -- Despite the availability of on-label products to treat diabetic retinopathy (DR), Genentech's off-label option, Avastin, is the predominant...